Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Study to Evaluate the Effects of Tempol (MBM-02) in COVID-19 Patients.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04729595
Recruitment Status : Recruiting
First Posted : January 28, 2021
Last Update Posted : April 5, 2022
Information provided by (Responsible Party):
Adamis Pharmaceuticals Corporation

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : June 30, 2022
Estimated Study Completion Date : September 30, 2022